Clinical trial
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients…
NCT00252642 · Virginia Commonwealth University, Other · Completed
Key facts
| NCT number | NCT00252642 |
|---|---|
| Title | Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C |
| Official title | The Impact of Peginterferon Alpha-2a Maintenance Therapy on Portal Hypertension in Patients With Chronic Hepatitis C Virus Infection and Advanced Fibrosis and Cirrhosis Enrolled in the HALT-C Trial |
| Lead sponsor | Virginia Commonwealth University, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Hepatitis C, Cirrhosis, Fibrosis |
| Intervention type | Drug |
| Interventions | Peginterferon Alpha-2a |
| Enrollment | 60 |
| Start date | Nov 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Nov 11, 2005 |
| Last update posted | Mar 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: